Shares of Crinetics Pharmaceuticals Inc. (CRNX), a clinical-stage pharmaceutical company developing novel therapeutics for endocrine diseases and endocrine-related tumors, have lost over 40% from their 52-week high of $62.53, recorded last November, and trade around $35.
The company's lead drug candidate is Paltusotine, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 agonist in development for the proposed treatment of people with acromegaly.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com